CHA ÀǰúÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ÀÌÀ¯È£
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : ½ÅÀåÀ̽Ä/±Þ¼º½ÅÁúȯ/¸¸¼º½ÅÁúȯ/Ç÷´¢/´Ü¹é´¢/Åõ¼®
  • Á÷ À§: Á¶±³¼ö
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
39 (±¹¿Ü)SCI Glucosamine hydrochloride exerts a protective effect against unilateral ureteral obstruction-induced renal fibrosis by attenuating TGF-¥â signaling.
38 (±¹³»)SCIE Serum osteoprotegerin is associated with vascular stiffness and the onset of new cardiovascular events in hemodialysis patients
37 (±¹³»)SCOPUS Åõ¼®È¯ÀÚÀÇ BÇü°£¿° ¹ÙÀÌ·¯½º ÀáÀç°¨¿°·ü
36 (±¹¿Ü)SCI Risk factors affecting seroconversion after influenza A/H1N1 vaccination in hemodialysis patients
35 (±¹¿Ü)SCI TGF-¥â sensitivity is determined by N-linked glycosylation of the type II TGF-¥â receptor
34 (±¹¿Ü)SCI 25-hydroxyvitamin D levels and vascular calcification in perdialysis and dialysis patients with chronic kidney disease
33 (±¹³»)KCI ±Ý¼º ½ÅºÎÀüÀ» µ¿¹ÝÇÑ ºÎµ¿È­¿¡ ÀÇÇÑ °íÄ®½·Ç÷Áõ¼º ½ÅÁõ 1¿¹
32 (±¹³»)KCI ÆÄ±¹ Ç×ÀÎÁöÁú ÁõÈıº ÀÇÁõ ȯÀÚÀÇ ÆÄÁ¾Ç÷°ü³»ÀÀ°í °ü·Ã ±Þ¼º ½Å¼Õ»ó 1¿¹
31 (±¹³»)KCI Intra-Renal Arterial Pseudoaneurysm Associated with Acute Pyelonephritis
30 (±¹³»)SCI MTHFR C677T polymorphism as a risk factor for vascular calcification in chronic hemodialysis patients
ÀÌÀüÆäÀÌÁö À̵¿ 11 12 13 14 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾Çհǰ­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729